Cerebrospinal uid (CSF) stula is a common neurosurgical complication, occurring in 1% to 27% of cases. e main clinical manifestations are postural headache, nausea, dizziness, photophobia, and tinnitus. is condition may be associated with inadequate wound healing and infection, meningitis, and pseudomeningocele, factors that increase patient morbidity and mortality.
INTRODUCTION
Cerebrospinal uid (CSF) stula is a common neurosurgical complication, occurring in 1% to 27% of cases. e main clinical manifestations are postural headache, nausea, dizziness, photophobia, and tinnitus. is condition may be associated with inadequate wound healing and infection, meningitis, and pseudomeningocele, factors that increase patient morbidity and mortality.
Despite the limitations, hermetic closure of the dura mater has been recommended for the prevention and treatment of CSF stula. In recent years, techniques have been developed to reinforce the site of the dura mater closure, such as additional suture, autologous tissue gra s, brin sealants, and collagen sponges. DuraSeal is a dura mater sealant consisting of polyethylene glycol hydrogel (PEG hydrogel), to be applied at the site of suture, and has been indicated for head and spinal surgery with opening of the dura mater.
METHODS
A systematic review was performed in MEDLINE, EMBASE, and Scielo/Lilacs databases, recovering a total of 365 articles using the following search strategies: ((duraseal OR dura seal OR polyethylene glycol hydrogel OR dura seal dural sealant system OR dura-seal OR polyethylene glycols OR dura seal xact adhesion barrier and sealant system OR hydrogel) AND (neurosurgical procedures OR neurosurgery OR cranial surgery)) AND random*. e analysis of 365 articles was based on their titles and abstracts. Six articles met the inclusion criteria (randomized clinical trial study design, comparing the use of DuraSeal to suture with or without complementary methods of dura mater closure, and having as outcome the development of CSF stula and other complications). ese articles were critically appraised using the Jadad score 1 .
RESULTS
Two studies were selected. Of these, one refers to the use of DuraSeal in head surgeries (Jadad: 1) 2 , and another to the use of DuraSeal in spinal surgeries (Jadad: 3) 3 . e study by Kim et al. 2 evaluated the use of DuraSeal in spinal surgeries. e sample included 158 patients who were randomized (102 patients in the intervention group and 56 in the control group). e primary outcome was CSF stula; the secondary outcome, other complications. Patient follow-up was performed during the immediate postoperative period, a er 30 and 90 days. is study demonstrated that the use of DuraSeal in spinal surgeries is associated with absolute risk reduction (ARR) in 35.6% (95% CI: 23.0%-48.2%) and NNT of 3 for CSF stula; there was no di erence between the control and intervention groups regarding the development of further complications. e study by Osbun et al. 3 analyzed the use of DuraSeal in head surgeries and consisted of 237 randomized patients (120 in the intervention group and 117 in the control group), having CSF stula as the primary outcome and other complications as the secondary outcome. Patients were followed for 30 days. ere was no decrease in the incidence of neurosurgical complications, including CSF leak, as well as incisional complications.
SYNTHESIS OF AVAILABLE EVIDENCE
when compared to suturing with or without brin sealant, showed a decrease in the absolute risk of CSF stula (ARR: 35.6% and NNT: 3), with no increased risk of complications.
when compared to suturing with or without brin sealant, showed no reduction in the absolute risk of neurosurgical complications, including CSF leak, and no decrease in the risk of incisional complications.
